Consistently, Wang et al. reported that renal cell carcinoma (RCC) tumors with high expression levels of stem cell genes had the highest sensitivity to immunotherapy targeting CTLA-4 [68]. The gene discussed is CTLA4; the disease is renal cell carcinoma.